You are here

New Indication for Pemetrexed In Metastatic NSCLC

Trial Demonstrated Significantly Improved Survival Rates

Pemetrexed for injection (Alimtra, Eli Lilly and Company) has received FDA approval for a new indication in combination with pembrolizumab (Keytruda, Merck) and platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. 

The approval was based on data from the phase 3 KEYNOTE-189 trial, which enrolled patients regardless of PD-L1 expression and had primary endpoints of overall survival (OS) and progression-free survival (PFS).  

KEYNOTE-189 demonstrated that Alimta, in combination with pembrolizumab plus platinum-based chemotherapy, resulted in significantly longer OS and PFS than ALIMTA plus platinum chemotherapy with placebo. 

Severe adverse reactions occurring in ≥20% of patients included fatigue, diarrhea, dyspnea, vomiting, nausea, rash, decreased appetite, constipation, and pyrexia.

Source: Eli Lilly and Company, January 31, 2019

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
More Than 32% of Patients Responded in Trial
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria